50 research outputs found

    Helicobacter pylori infection of gastric cancercells elevates the level of expression and activation of protein kinase D2

    No full text
    Aim: To test the hypothesis, whether H. pylori infection may affect the level of PKD2 expression and/or activation in gastric cancer cells. Methods: Studies were performed on AGS human gastric adenocarcinoma cell line, gastric tissues samples from 36 cases of different histological variants of gastric cancer. Immunohistochemical, cell and molecular biology, bacteriological and biochemical approaches have been used in this study. Results: H. pylori 16S rRNA gene was detected in 97% cases of gastric tumors, and in 83% of cases cΠ°gA gene was detected. In all tested adenocarcinoma samples cagA+ H. pylori was revealed. These cases were characterized by high level of PKD1/2 expression and autophosphorylation. In adenogenic cancer samples the presence of cagA– H. pylori was identified. Carcinoid and nondifferentiated gastric cancers contain H. pylori, with very low numbers of cagA+ copies. All cases of gastric tumors with cagA– H. pylori had very low levels of PKD1/2 autophosphorylation. AGS cell line infection with cagA– and cagA+ H. Ρ€ylori resulted in elevation of PKD2 expression levels in 3.29 and 3.66 times respectively (p < 0.001). In cells infected by cag+ H. Ρ€ylori the level of PKD2 transphosphorylation was 1.39 higher than in cells infected by cagA– H. pylori. For PKD2 autophosphorylation this difference was even higher β€” 3.27 times (p < 0.001). Conclusion: H. pylori infection enhanced the level of protein kinase D2 expression, trans- and autophosphorylation. The level of PKD2 autophosphorylation/activation was higher in AGS cell line inoculated of with cag+ H. pylori than in AGS cells with cagA– H. pylori. These suggest that H. pylori induces activation of PKD1/2 and could exploit PKD2 mediated signaling pathways that may contribute to the pathogenesis of gastric cancer

    ЦСфалоспорины Ρ‚Ρ€Π΅Ρ‚ΡŒΠ΅Π³ΠΎ поколСния Π² Π»Π΅Ρ‡Π΅Π½ΠΈΠΈ Π³ΠΎΠ½ΠΎΡ€Π΅ΠΈ

    Get PDF
    The article presents the data on antibiotic resistance and N. gonorrhoeae mechanisms for developing resistance to antimicrobial drugs belonging to different pharmacologic groups and applied for causal treatment of gonorrhea. The article proves the key problem related to the treatment of gonococcal infection in Russia lies in the prevalence of strains being resistant to most of the antibacterial drugs that used to be applied in the clinical practice on a broad scale and efficiently. So, cephalosporins of the third generation are presently the only drug type that N. gonorrhoeae remains sensitive to. Their application ensures the maximum efficacy against the gonococcal infection. According to the presentday international recommendations complying with the WHO criteria as well as accumulated experience, cefixime, a drug belonging to cephalosporins of the third generation, can be a drug of choice for the antibacterial therapy of gonorrhea along with ceftriaxon.ΠŸΡ€Π΅Π΄ΡΡ‚Π°Π²Π»Π΅Π½Ρ‹ Π΄Π°Π½Π½Ρ‹Π΅ ΠΎ cостоянии антибиотикорСзистСнтности ΠΈ ΠΌΠ΅Ρ…Π°Π½ΠΈΠ·ΠΌΠ°Ρ… развития устойчивости N. gonorrhoeae ΠΊ Π°Π½Ρ‚ΠΈΠΌΠΈΠΊΡ€ΠΎΠ±Π½Ρ‹ΠΌ ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚Π°ΠΌ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… фармакологичСских Π³Ρ€ΡƒΠΏΠΏ, примСняСмым для этиотропной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π³ΠΎΠ½ΠΎΡ€Π΅ΠΈ. Показано, Ρ‡Ρ‚ΠΎ основная ΠΏΡ€ΠΎΠ±Π»Π΅ΠΌΠ° Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ Π² России Π² настоящСС врСмя Π·Π°ΠΊΠ»ΡŽΡ‡Π°Π΅Ρ‚ΡΡ Π² распространСнности ΡˆΡ‚Π°ΠΌΠΌΠΎΠ² возбудитСля, устойчивых ΠΊ Π±ΠΎΠ»ΡŒΡˆΠΈΠ½ΡΡ‚Π²Ρƒ Π°Π½Ρ‚ΠΈΠ±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½Ρ‹Ρ… ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ², Ρ€Π°Π½Π΅Π΅ ΡˆΠΈΡ€ΠΎΠΊΠΎ ΠΈ эффСктивно ΠΏΡ€ΠΈΠΌΠ΅Π½ΡΠ²ΡˆΠΈΡ…ΡΡ Π² клиничСской ΠΏΡ€Π°ΠΊΡ‚ΠΈΠΊΠ΅. ΠŸΠΎΡΡ‚ΠΎΠΌΡƒ Π½Π° сСгодняшний дСнь СдинствСнным классом ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ², ΠΊ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹ΠΌ N. gonorrhoeae Π΄ΠΎ сих ΠΏΠΎΡ€ сохраняСт Ρ‡ΡƒΠ²ΡΡ‚Π²ΠΈΡ‚Π΅Π»ΡŒΠ½ΠΎΡΡ‚ΡŒ ΠΈ ΠΏΡ€ΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΠΊΠΎΡ‚ΠΎΡ€Ρ‹Ρ… обСспСчиваСт Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ высокий ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ излСчСнности Π³ΠΎΠ½ΠΎΠΊΠΎΠΊΠΊΠΎΠ²ΠΎΠΉ ΠΈΠ½Ρ„Π΅ΠΊΡ†ΠΈΠΈ, ΡΠ²Π»ΡΡŽΡ‚ΡΡ цСфалоспорины Ρ‚Ρ€Π΅Ρ‚ΡŒΠ΅Π³ΠΎ поколСния. Богласно соврСмСнным ΠΌΠ΅ΠΆΠ΄ΡƒΠ½Π°Ρ€ΠΎΠ΄Π½Ρ‹ΠΌ рСкомСндациям ΠΈ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½Π½ΠΎΠΌΡƒ ΠΎΠΏΡ‹Ρ‚Ρƒ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ΠΎΠ² Π²Ρ‹Π±ΠΎΡ€Π° для Π°Π½Ρ‚ΠΈΠ±Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ°Π»ΡŒΠ½ΠΎΠΉ Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π³ΠΎΠ½ΠΎΡ€Π΅ΠΈ, ΡΠΎΠΎΡ‚Π²Π΅Ρ‚ΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΡ… критСриям Π’ΠžΠ—, наряду с цСфтриаксоном ΠΌΠΎΠΆΠ΅Ρ‚ ΡΠ²Π»ΡΡ‚ΡŒΡΡ ΠΏΡ€Π΅ΠΏΠ°Ρ€Π°Ρ‚ Π³Ρ€ΡƒΠΏΠΏΡ‹ цСфалоспоринов Ρ‚Ρ€Π΅Ρ‚ΡŒΠ΅Π³ΠΎ поколСния для ΠΏΠ΅Ρ€ΠΎΡ€Π°Π»ΡŒΠ½ΠΎΠ³ΠΎ ΠΏΡ€ΠΈΠ΅ΠΌΠ° цСфиксим

    Π˜Π·ΡƒΡ‡Π΅Π½ΠΈΠ΅ эффСктивности ΠΈΠ·ΠΎΠ»ΠΈΡ€ΡƒΡŽΡ‰Π΅Π³ΠΎ ΠΊΡ€Π΅ΠΌΠ° Π‘Π°Ρ€ΡŒΠ΅Π΄Π΅Ρ€ΠΌ ΠΏΡ€ΠΈ Π΄Π΅Ρ€ΠΌΠ°Ρ‚ΠΎΠ·Π°Ρ…

    Get PDF
    Goal. The aim of the study is evaluation of the effectiveness of a barrier cream Bariederm in combined therapy of dermatoses. Materials and Methods. 3 groups of patients were examined: 32 patients with allergic contact dermatitis, 22 female patients with cold and wind induced dermatitis and 23 children aged 5 years and under with cutaneons mastocytosis. All of them were treated with Bariederm cream. Results. Including of Bariederm cream in combined treatment fetched to increase of clinical efficiency in treatment of dermatoses. Bariederm cream is also well tolerated.ЦСль. Π˜Π·ΡƒΡ‡Π΅Π½ΠΈΠ΅ эффСктивности ΠΈΠ·ΠΎΠ»ΠΈΡ€ΡƒΡŽΡ‰Π΅Π³ΠΎ ΠΊΡ€Π΅ΠΌΠ° Π‘Π°Ρ€ΡŒΠ΅Π΄Π΅Ρ€ΠΌ Π² комплСксной Ρ‚Π΅Ρ€Π°ΠΏΠΈΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΠΊΠΎΠΆΠΈ Ρƒ взрослых ΠΈ Π΄Π΅Ρ‚Π΅ΠΉ. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π» ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹. Наблюдали 3 Π³Ρ€ΡƒΠΏΠΏΡ‹ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ²: 1-ю Π³Ρ€ΡƒΠΏΠΏΡƒ составили 32 Ρ‡Π΅Π»ΠΎΠ²Π΅ΠΊΠ°, Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… аллСргичСским ΠΊΠΎΠ½Ρ‚Π°ΠΊΡ‚Π½Ρ‹ΠΌ Π΄Π΅Ρ€ΠΌΠ°Ρ‚ΠΈΡ‚ΠΎΠΌ, Π²ΠΎ 2-ю Π³Ρ€ΡƒΠΏΠΏΡƒ вошли 22 ΠΆΠ΅Π½Ρ‰ΠΈΠ½Ρ‹, ΡΡ‚Ρ€Π°Π΄Π°Π²ΡˆΠΈΠ΅ простым Ρ€Π°Π·Π΄Ρ€Π°ΠΆΠΈΡ‚Π΅Π»ΡŒΠ½Ρ‹ΠΌ Π΄Π΅Ρ€ΠΌΠ°Ρ‚ΠΈΡ‚ΠΎΠΌ ΠΎΡ‚ воздСйствия Π²Π΅Ρ‚Ρ€Π° ΠΈ Ρ…ΠΎΠ»ΠΎΠ΄Π° Π² Π·ΠΈΠΌΠ½Π΅Π΅ врСмя, Π² 3-ю - 23 Ρ€Π΅Π±Π΅Π½ΠΊΠ° Π² возрастС Π΄ΠΎ 5 Π»Π΅Ρ‚ с ΠΊΠΎΠΆΠ½Ρ‹ΠΌΠΈ Ρ„ΠΎΡ€ΠΌΠ°ΠΌΠΈ мастоцитоза. Π’ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡƒΡŽ Ρ‚Π΅Ρ€Π°ΠΏΠΈΡŽ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² Π²ΠΊΠ»ΡŽΡ‡Π°Π»ΠΈ ΠΊΡ€Π΅ΠΌ Π‘Π°Ρ€ΡŒΠ΅Π΄Π΅Ρ€ΠΌ. Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹. Π’ΠΊΠ»ΡŽΡ‡Π΅Π½ΠΈΠ΅ ΠΊΡ€Π΅ΠΌΠ° Π‘Π°Ρ€ΡŒΠ΅Π΄Π΅Ρ€ΠΌ Π² ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠ½ΡƒΡŽ Ρ‚Π΅Ρ€Π°ΠΏΠΈΡŽ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚ΠΎΠ² ΠΏΡ€ΠΈΠ²Π΅Π»ΠΎ ΠΊ сущСствСнному Π²ΠΎΠ·Ρ€Π°ΡΡ‚Π°Π½ΠΈΡŽ клиничСского эффСкта. ΠžΡ‚ΠΌΠ΅Ρ‡Π΅Π½Π° Ρ…ΠΎΡ€ΠΎΡˆΠ°Ρ ΠΏΠ΅Ρ€Π΅Π½ΠΎΡΠΈΠΌΠΎΡΡ‚ΡŒ ΠΊΡ€Π΅ΠΌΠ° Π‘Π°Ρ€ΡŒΠ΅Π΄Π΅Ρ€ΠΌ ΠΏΠ°Ρ†ΠΈΠ΅Π½Ρ‚Π°ΠΌΠΈ

    Discrimination between Streptococcus pneumoniae and Streptococcus mitis based on sorting of their MALDI mass spectra

    Get PDF
    AbstractAccurate species-level identification of alpha-hemolytic (viridans) streptococci (VGS) is very important for understanding their pathogenicity and virulence. However, an extremely high level of similarity between VGS within the mitis group (S. pneumoniae, S. mitis, S. oralis and S. pseudopneumoniae) often results in misidentification of these organisms. Earlier, matrix-assisted laser desorption ionization–time of flight mass spectrometry (MALDI-TOF MS) has been suggested as a tool for the rapid identification of S. pneumoniae. However, by using Biotyper 3.0 (Bruker) or Vitek MS (bioMΓ©rieux) databases, Streptococcus mitis/oralis species can be erroneously identified as S. pneumoniae. ClinProTools 2.1 software was used for the discrimination of MALDI-TOF mass spectra of 25 S. pneumoniae isolates, 34 S. mitis and three S. oralis. Phenotypical tests and multilocus gene typing schemes for the S. pneumoniae (http://spneumoniae.mlst.net/) and viridans streptococci (http://viridans.emlsa.net/) were used for the identification of isolates included in the study. The classifying model was generated based on different algorithms (Genetic Algorithm, Supervised Neural Network and QuickClassifier). In all cases, values of sensitivity and specificity were found to be equal or close to 100%, allowing discrimination of mass spectra of different species. Three peaks (6949, 9876 and 9975 m/z) were determined conferring the maximal statistical weight onto each model built. We find this approach to be promising for viridans streptococci discrimination

    Immunohistochemical studies of protein kinase D (PKD) 2 expression in malignant human lymph

    No full text
    Aim: To study the PKD2 expression, autophosphorylation and localization in reactive lymph nodes and tumors of lymphoid tissues. Materials and Methods: Specific antibodies, which recognize PKD1/2 or PKD2 and autophosphorylated PKD1/2, were used for immunohistochemical and biochemical studies of tonsils, reactive lymph nodes, tumor samples of non-Hodgkin’s lymphoma (NHL) and Hodgkin’s lymphoma (HL). Results: Immunohistochemical and biochemical analysis of PKD1 and PKD2 expression showed PKD2 expression in tonsils, reactive lymph nodes and tumor tissues from patients with NHL and HL. Furthermore, we were not able to reveal PKD1 expression in studied lymphoid tissues. In tonsils and reactive lymph nodes the PKD2 expression was detected in T and B cell zones with highest level in germinal centers of lymphoid follicles and the maximum level of autophosphorylation in the light zones of the germinal centers. We found that low level of PKD2 expression and autophosphorylation was characteristic feature for mantle cell lymphomas, Burkitt’s lymphomas, and in 50% of CLL/small lymphocytic lymphomas. Lymphoma cells of germinal center origin and with activated B cell phenotype (diffuse large B cell lymphomas, HL) and anaplastic large cells lymphoma demonstrated the high level of PKD2 expression and autophosphorylation. Conclusions: The level of PKD2 expression and autophosphorylation in neoplastic cells corresponds to the expression pattern of this kinase in their normal analogs, and to the level of cell differentiation and activation.ЦСль: ΠΈΠ·ΡƒΡ‡ΠΈΡ‚ΡŒ ΡΠΊΡΠΏΡ€Π΅ΡΡΠΈΡŽ, аутофосфорилированиС ΠΈ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°Ρ†ΠΈΡŽ PKD2 Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… Ρ€Π΅Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½Ρ‹Ρ… Π»ΠΈΠΌΡ„aтичСских ΡƒΠ·Π»ΠΎΠ² ΠΈ опухолях Π»ΠΈΠΌΡ„ΠΎΠΈΠ΄Π½ΠΎΠΉ Ρ‚ΠΊΠ°Π½ΠΈ. ΠœΠ°Ρ‚Π΅Ρ€ΠΈΠ°Π»Ρ‹ ΠΈ ΠΌΠ΅Ρ‚ΠΎΠ΄Ρ‹: спСцифичСскиС Π°Π½Ρ‚ΠΈΡ‚Π΅Π»Π°, Ρ€Π°ΡΠΏΠΎΠ·Π½Π°ΡŽΡ‰ΠΈΠ΅ PKD1/2 ΠΈΠ»ΠΈ PKD2 ΠΈ Π°ΡƒΡ‚ΠΎΡ„ΠΎΡΡ„ΠΎΡ€ΠΈΠ»ΠΈΡ€ΠΎΠ²Π°Π½Π½ΡƒΡŽ PKD1/2, Π±Ρ‹Π»ΠΈ ΠΈΡΠΏΠΎΠ»ΡŒΠ·ΠΎΠ²Π°Π½Ρ‹ для иммуногистохимичСского ΠΈ биохимичСского Π°Π½Π°Π»ΠΈΠ·Π° ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π½Π΅Π±Π½Ρ‹Ρ… ΠΌΠΈΠ½Π΄Π°Π»ΠΈΠ½, Ρ€Π΅Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½Ρ‹Ρ… Π»ΠΈΠΌΡ„aтичСских ΡƒΠ·Π»ΠΎΠ², Π±ΠΈΠΎΠΏΡ‚Π°Ρ‚ΠΎΠ² ΠΎΠΏΡƒΡ…ΠΎΠ»Π΅ΠΉ Ρƒ Π±ΠΎΠ»ΡŒΠ½Ρ‹Ρ… нСходТкинскими злокачСствСнными Π»ΠΈΠΌΡ„ΠΎΠΌΠ°ΠΌΠΈ (НΠ₯Π›) ΠΈ Π»ΠΈΠΌΡ„ΠΎΠΌΠΎΠΉ Π₯ΠΎΠ΄ΠΆΠΊΠΈΠ½Π° (Π›Π₯). Π Π΅Π·ΡƒΠ»ΡŒΡ‚Π°Ρ‚Ρ‹: ΠΏΡ€ΠΈ иммуногистохимичСском ΠΈ биохимичСском исслСдовании выявлСна экспрСссия PKD2 Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… ΠΌΠΈΠ½Π΄Π°Π»ΠΈΠ½, Π³ΠΈΠΏΠ΅Ρ€ΠΏΠ»Π°Π·ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… лимфатичСских ΡƒΠ·Π»ΠΎΠ² ΠΈ Ρ€Π°Π·Π»ΠΈΡ‡Π½Ρ‹Ρ… гистологичСских Ρ„ΠΎΡ€ΠΌ НΠ₯Π› ΠΈ Π›Π₯. ЭкспрСссия PKD1 Π² ΠΈΠ·ΡƒΡ‡Π΅Π½Π½Ρ‹Ρ… Π½Π°ΠΌΠΈ Π»ΠΈΠΌΡ„ΠΎΠΈΠ΄Π½Ρ‹Ρ… тканях выявлСна Π½Π΅ Π±Ρ‹Π»Π°. ЭкспрСссия PKD2 Π±Ρ‹Π»Π° выявлСна Π² T- ΠΈ B-ΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½Ρ‹Ρ… Π·ΠΎΠ½Π°Ρ… ΠΌΠΈΠ½Π΄Π°Π»ΠΈΠ½ ΠΈ Ρ€Π΅Π°ΠΊΡ‚ΠΈΠ²Π½ΠΎ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½Ρ‹Ρ… лимфатичСских ΡƒΠ·Π»ΠΎΠ². НаиболСС высокий ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ экспрСссии отмСчался Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… Π·Π°Ρ€ΠΎΠ΄Ρ‹ΡˆΠ΅Π²Ρ‹Ρ… Ρ†Π΅Π½Ρ‚Ρ€ΠΎΠ² Π»ΠΈΠΌΡ„ΠΎΠΈΠ΄Π½Ρ‹Ρ… Ρ„ΠΎΠ»Π»ΠΈΠΊΡƒΠ»ΠΎΠ², ΠΌΠ°ΠΊΡΠΈΠΌΠ°Π»ΡŒΠ½Ρ‹ΠΉ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ аутофосфорилирования β€” Π² свСтлых Π·ΠΎΠ½Π°Ρ… Π·Π°Ρ€ΠΎΠ΄Ρ‹ΡˆΠ΅Π²Ρ‹Ρ… Ρ†Π΅Π½Ρ‚Ρ€ΠΎΠ². ΠžΠ±Π½Π°Ρ€ΡƒΠΆΠ΅Π½ΠΎ, Ρ‡Ρ‚ΠΎ Π½ΠΈΠ·ΠΊΠΈΠΉ ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ экспрСссии ΠΈ аутофосфорилирования PKD2 являСтся Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€Π½ΠΎΠΉ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡ‚ΡŒΡŽ Π»ΠΈΠΌΡ„ΠΎΠΌ ΠΈΠ· ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΌΠ°Π½Ρ‚ΠΈΠΉΠ½ΠΎΠΉ Π·ΠΎΠ½Ρ‹, Π»ΠΈΠΌΡ„ΠΎΠΌΡ‹ Π‘Π΅Ρ€ΠΊΠΈΡ‚Ρ‚Π°, Π² 50% случаях Π»ΠΈΠΌΡ„ΠΎΠΌ ΠΈΠ· ΠΌΠ°Π»Ρ‹Ρ… Π»ΠΈΠΌΡ„ΠΎΡ†ΠΈΡ‚ΠΎΠ²/Π₯Π›Π›. ΠšΠ»Π΅Ρ‚ΠΊΠΈ Π»ΠΈΠΌΡ„ΠΎΠΌ, Π²ΠΎΠ·Π½ΠΈΠΊΠ°ΡŽΡ‰ΠΈΡ… ΠΈΠ· ΠΊΠ»Π΅Ρ‚ΠΎΠΊ Π·Π°Ρ€ΠΎΠ΄Ρ‹ΡˆΠ΅Π²Ρ‹Ρ… Ρ†Π΅Π½Ρ‚Ρ€ΠΎΠ² с Ρ„Π΅Π½ΠΎΡ‚ΠΈΠΏΠΎΠΌ Π°ΠΊΡ‚ΠΈΠ²ΠΈΡ€ΠΎΠ²Π°Π½Π½Ρ‹Ρ… B-ΠΊΠ»Π΅Ρ‚ΠΎΠΊ (диффузная Π»ΠΈΠΌΡ„ΠΎΠΌΠ° ΠΈΠ· ΠΊΡ€ΡƒΠΏΠ½Ρ‹Ρ… B-ΠΊΠ»Π΅Ρ‚ΠΎΠΊ, Π›Π₯), Π° Ρ‚Π°ΠΊΠΆΠ΅ анапластичСская крупноклСточная Π»ΠΈΠΌΡ„ΠΎΠΌΠ° Ρ…Π°Ρ€Π°ΠΊΡ‚Π΅Ρ€ΠΈΠ·ΠΎΠ²Π°Π»ΠΈΡΡŒ высоким ΡƒΡ€ΠΎΠ²Π½Π΅ΠΌ экспрСссии ΠΈ аутофосфорилирования PKD2. Π’Ρ‹Π²ΠΎΠ΄Ρ‹: ΡƒΡ€ΠΎΠ²Π΅Π½ΡŒ экспрСссии ΠΈ аутофосфорилирования PKD2 Π² ΠΊΠ»Π΅Ρ‚ΠΊΠ°Ρ… Π½ΠΎΠ²ΠΎΠΎΠ±Ρ€Π°Π·ΠΎΠ²Π°Π½ΠΈΠΉ соотвСтствуСт особСнностям экспрСссии этих ΠΊΠΈΠ½Π°Π· Π² ΡΠΎΠΎΡ‚Π²Π΅Ρ‚ΡΡ‚Π²ΡƒΡŽΡ‰ΠΈΡ… Π½ΠΎΡ€ΠΌΠ°Π»ΡŒΠ½Ρ‹Ρ… Π°Π½Π°Π»ΠΎΠ³Π°Ρ…, ΡƒΡ€ΠΎΠ²Π½ΡŽ ΠΊΠ»Π΅Ρ‚ΠΎΡ‡Π½ΠΎΠΉ Π΄ΠΈΡ„Ρ„Π΅Ρ€Π΅Π½Ρ†ΠΈΡ€ΠΎΠ²ΠΊΠΈ ΠΊΠ»Π΅Ρ‚ΠΎΠΊ ΠΈ ΠΈΡ… Π°ΠΊΡ‚ΠΈΠ²Π°Ρ†ΠΈΠΈ

    PNEUMOCOCCAL INFECTION β€” IN THE CENTRE OF ATTENTION AGAIN

    No full text
    This article present a general review on pneumococcal infection, its prevalence, clinic types in children in Russia and worldwide. Description of S. pneumoniae serotypes' distribution and its influence at clinical manifestation of pneumococcal infection and vaccination effectiveness is provided. Author evaluates perspectives of pneumococcal infection prevention by vaccination with pneumococcal conjugated 7-valent vaccine in Russia.Key words: children, pneumococcal infection, vaccination, pneumococcal conjugated 7 valent vaccine.(Voprosy sovremennoi pediatrii β€” Current Pediatrics. 2009;8(3):82-87)</em

    PNEUMOCOCCAL INFECTION β€” IN THE CENTRE OF ATTENTION AGAIN

    No full text
    This article present a general review on pneumococcal infection, its prevalence, clinic types in children in Russia and worldwide. Description of S. pneumoniae serotypes' distribution and its influence at clinical manifestation of pneumococcal infection and vaccination effectiveness is provided. Author evaluates perspectives of pneumococcal infection prevention by vaccination with pneumococcal conjugated 7-valent vaccine in Russia.Key words: children, pneumococcal infection, vaccination, pneumococcal conjugated 7 valent vaccine.(Voprosy sovremennoi pediatrii β€” Current Pediatrics. 2009;8(3):82-87
    corecore